Systemic Bio Named a Top 10 Finalist for the SLAS 2025 Innovation Award

Company Overview - Systemic Bio, a subsidiary of 3D Systems, focuses on accelerating drug discovery and development through its proprietary h-VIOS platform, which utilizes bioprinted tissues to provide human-relevant data [1][6] - The company was founded in 2022 and leverages advanced bioprinting technology to create precise healthy and diseased tissue models [6][8] Innovation Recognition - Systemic Bio has been selected as a Top 10 Finalist for the SLAS 2025 Innovation Award, highlighting the innovative potential of its h-VIOS platform [1][2] - The SLAS Innovation Award recognizes technologies that significantly impact laboratory science and automation [2] Technological Advancements - The h-VIOS platform addresses challenges in preclinical testing by producing bioprinted tissue models that accurately mimic human organ systems [3] - Systemic Bio operates from a state-of-the-art facility in Houston, capable of producing thousands of tissue models under a Quality Management System (QMS) [3] Upcoming Presentation - Systemic Bio will present its h-VIOS platform at the SLAS Conference in San Diego on January 27, 2025, with the award winner announced on January 29, 2025 [4]